Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Hemophilia (July 2016)

Posted by Matt Breese on Jul 29, 2016

Find me on:

According to our recent payer coverage analysis for Hemophilia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for Hemophilia treatments shows that commercial and managed medcaid formularies cover products nearly identically on average, whereas health exchange formularies restrict 75% of U.S. lives.


Source: MMIT data as of Q3 2016

Trends: One trend is the expanded role of specialty pharmacies with Hemophilia treatment plans. Many manufacturers and payers partner to form integrated networks to streamline medication time-to-fill. Additionally Hemophilia manufacturers utilize a unique strategy to invest in patients rather than providers when it comes to small financial gifts and programs, which is proving successful in this space.

To read the full Reality Check on Hemophilia treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check


Topics: Specialty, Market Access, Payer, Branding & Marketing